UB Paderborn / Katalog / Suche / in CDI

1 – 19 von 19

Sortiert nach

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

Nature medicine, 2011-07, Vol.17 (7), p.875-882

2011

Link zum Volltext

Verfügbarkeit prüfen

ABCDE steps to prevent heart disease in breast cancer survivors

Circulation (New York, N.Y.), 2014-10, Vol.130 (18), p.e157-e159

2014

Link zum Volltext

Verfügbarkeit prüfen

An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression

Cell reports (Cambridge), 2015-05, Vol.11 (5), p.715-726

2015

Link zum Volltext

Verfügbarkeit prüfen

Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These Tumor Types From Morphologically and Phenotypically Similar Lymphomas

The American journal of surgical pathology, 2011-10, Vol.35 (10), p.1531-1539

2011

Link zum Volltext

Verfügbarkeit prüfen

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

Cancer cell, 2010-12, Vol.18 (6), p.580-589

2010

Link zum Volltext

Verfügbarkeit prüfen

Breast Cancer Chemotherapy and Your Heart

Circulation (New York, N.Y.), 2014-06, Vol.129 (25)

2014

Link zum Volltext

Verfügbarkeit prüfen

T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation

Human pathology, 2017-07, Vol.65, p.166-174

2017

Link zum Volltext

Verfügbarkeit prüfen

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide

Clinical cancer research, 2011-05, Vol.17 (10), p.3259-3271

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2796-2796

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT047-CT047

2017

Link zum Volltext

Verfügbarkeit prüfen

Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression

Blood, 2014-12, Vol.124 (21), p.4719-4719

2014

Link zum Volltext

Verfügbarkeit prüfen

Cardiology patient page. Breast cancer chemotherapy and your heart

Circulation (New York, N.Y.), 2014-06, Vol.129 (25), p.e680-e682

2014

Link zum Volltext

Verfügbarkeit prüfen

Constitutive Canonical NF-I[ordmB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

Cancer cell, 2010-12, Vol.18 (6), p.580-589

2010

Link zum Volltext

Verfügbarkeit prüfen

Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B-cell like diffuse large B-cell lymphoma

Cancer cell, 2010-12, Vol.18 (6), p.580-589

2010

Link zum Volltext

Verfügbarkeit prüfen

Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide

Clinical cancer research, 2011-03, Vol.17 (10), p.3259-3271

2011

Link zum Volltext

Verfügbarkeit prüfen

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.(Cyclin dependent kinase 1)(breast cancer)(Poly

Nature medicine, 2011-07, Vol.17 (7), p.875

2011

Link zum Volltext

Verfügbarkeit prüfen

Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors

Bioorganic & medicinal chemistry letters, 2004-06, Vol.14 (11), p.2817-2822

2004

Link zum Volltext

Verfügbarkeit prüfen

Duurzame wijk Tivoli: naar een nieuw soort stadsleven in Brussel?

Brussels studies, 2016-12

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 19 von 19

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(19)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

Cancer Cell
(3)
Circulation
(3)
Cancer Research
(2)
Cell Reports
(2)
Clinical Cancer Research
(2)
Nature Medicine
(2)
Bioorganic & Medicinal Chemistry Letters
(1)
Blood
(1)
Brussels Studies
(1)
Human Pathology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

ABCDE steps to prevent heart disease in breast cancer survivors

An Oncogenic Role for Alternative NF-κB Signaling in DLBCL Revealed upon Deregulated BCL6 Expression

Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These Tumor Types From Morphologically and Phenotypically Similar Lymphomas

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

Breast Cancer Chemotherapy and Your Heart

T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation

Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide

Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity

Abstract CT047: Phase 1 dose-escalation study of the CDK inhibitor dinaciclib in combination with the PARP inhibitor veliparib in patients with advanced solid tumors

Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression

Cardiology patient page. Breast cancer chemotherapy and your heart

Constitutive Canonical NF-I[ordmB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

Constitutive canonical NF-κB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B-cell like diffuse large B-cell lymphoma

Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.(Cyclin dependent kinase 1)(breast cancer)(Poly

Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors

Duurzame wijk Tivoli: naar een nieuw soort stadsleven in Brussel?

Suchergebnisse filtern